Brain Drain And Recruitment Risks for EMA post UK Brexit Vote

 
• By Maureen Kenny
  
Generate a summary of this article
Listen to this article
Beta

Retaining existing and recruiting new staff could be a challenge for the London-based European Medicines Agency as a result of the uncertainty over the future location of the agency following the decision by the UK to leave the EU.

Exit

The ability of the London-based European Medicines Agency to retain and recruit staff over the next few years could be compromised by the decision of the UK to leave the EU, experts suggest. In addition, the jobs of regulatory affairs professionals working in the pharmaceutical industry could be at risk if, as expected, the EMA has to relocate – with companies moving jobs out of the UK and closer to where the agency eventually has its next home.

There is no knowing what compromises will be reached as the UK’s departure from the EU is negotiated in the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

EU Pharma Reform: What You Need to Know Now

 
• By Anabel Costa-Ferreira and Ian Schofield

As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Nancy Test Circulable Section Geography

 
• By Brian Bossetta

This is a short description

Diversity Action Plans: What To Submit And When

 
• By Nielsen Hobbs

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.